Journal
BIOMEDICINES
Volume 11, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines11071908
Keywords
incremental hemodialysis; sodium; glucose cotransporter-2 inhibitor; residual kidney function; end stage renal disease; diabetic kidney disease; kidney replacement therapy
Ask authors/readers for more resources
This study retrospectively describes the safety and efficacy of SGLT2i in preserving residual kidney function (RKF) in diabetic patients undergoing incremental hemodialysis (iHD). The results showed that all patients preserved RKF after the introduction of SGLT2i and there was a significant improvement in residual kidney urea clearance (KrU) at 12 months. There were also significant improvements in blood pressure, uric acid levels, hemoglobin A1c, urine albumin/creatinine ratio (UACR), and 24-hour proteinuria. The use of SGLT2i in diabetic patients starting iHD appears to be safe and effective in preserving RKF.
SGLT-2i are the new standard of care for diabetic kidney disease (DKD), but previous studies have not included patients on kidney replacement therapy (KRT). Due to their high risk of cardiovascular, renal complications, and mortality, these patients would benefit the most from this therapy. Residual kidney function (RKF) conveys a survival benefit and cardiovascular health among hemodialysis (HD) patients, especially those on incremental hemodialysis (iHD). We retrospectively describe the safety and efficacy of SGLT2i regarding RKF preservation in seven diabetic patients with different clinical backgrounds who underwent iHD (one or two sessions per week) during a 12-month follow-up. All patients preserved RKF, measured as residual kidney urea clearance (KrU) in 24 h after the introduction of SGLT2i. KrU levels improved significantly from 4.91 & PLUSMN; 1.14 mL/min to 7.28 & PLUSMN; 1.68 mL/min at 12 months (p = 0.028). Pre-hemodialysis blood pressure improved 9.95% in mean systolic blood pressure (SBP) (p = 0.015) and 10.95% in mean diastolic blood pressure (DBP) (p = 0.041); as a result, antihypertensive medication was modified. Improvements in blood uric acid, hemoglobin A1c, urine albumin/creatinine ratio (UACR), and 24 h proteinuria were also significant. Regarding side effects, two patients developed uncomplicated urinary tract infections that were resolved. No other complications were reported. The use of SGLT2i in our sample of DKD patients starting iHD on a 1-2 weekly regimen appears to be safe and effective in preserving RKF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available